Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idelalisib
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Idelalisib is an oral small molecule antineoplastic agent classified as a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. It is primarily used in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL), and as monotherapy for relapsed follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. By inhibiting PI3Kδ, which is predominantly expressed in leukocytes and plays a key role in B-cell receptor signaling, idelalisib disrupts pathways critical to the proliferation, survival, homing, and retention of malignant B-cells within lymphoid tissues and bone marrow. This results in apoptosis of malignant cells and inhibition of their migration and adhesion[1][3][5][9].
- Brand names
- Zydelig
- Other names
- idelalisib
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on idelalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idelalisib.